Pharmaceuticals

IMPACT THERAP-B

IMPACT THERAP-B released FY2024 annual earnings on May 5, 2026 (BJT), actual revenue HKD 36.31 M, actual EPS HKD -1.3752

7630.HK released FY2025 Annual Earnings on May 5, 2026 (BJT), with actual revenue of HKD 41.81 M and EPS of HKD -1.415

CENTRAL DEV H

FAMEGLOW

ZHONGSHENJIANYE

TJCD

NEW GONOW RV

REALWAY CAPITAL

ZXZN QI-HOUSE

51WORLD

CH CITY INFRA

EASYHOLD GROUP

07630

Impact Therapeutics, a biotech firm specializing in synthetic lethality drugs, made a strong debut on the Hong Kong stock market, with shares doubling on the first day. The company raised approximately HK$844 million ($108 million) through its IPO, which was oversubscribed by over 2000 times. Its core product, senaparib, is a PARP inhibitor approved in China for advanced ovarian cancer. Despite significant R&D losses, the company aims to use IPO proceeds to further develop senaparib and other pipeline drugs, targeting a growing market for precision cancer therapies.

benzinga_article

Goldman Sachs

CICC

HUADONG MEDICINE

AstraZeneca

AstraZeneca PLC

HENGRUI PHARMA

Hengrui Pharma

TENCENT

Tencent

JUNSHI BIO

Junshi Biosciences

WUXI APPTEC

WuXi AppTec

GS Hldg R

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Precision-Drug maker Impact Therapeutics Ignites IPO Frenzy

IMPACT THERAP-B was listed on the Hong Kong stock market, becoming the first innovative oncology drug company based on the "synthetic lethality" mechanism. On its first day of trading, the stock price surged by 108.26%, closing at HKD 41.86. This IPO globally offered approximately 41.98 million shares, raising a net amount of HKD 759 million, with the public offering portion oversubscribed by more than 2,281 times. Although the company is still in a state of significant losses, with a projected net loss of HKD 296 million in 2025, its core product, Senaparib, has been approved and included in the medical insurance catalog, becoming the focus of market attention

BambooWorks

WUXI BIO

WuXi Biologics

Hong Kong stocks "synthetic death" first stock IMPACT THERAP-B first listing stock price doubled

IMPACT THERAP-Bclosed at $32.16 on gray market yesterday, up 60.0% from the listing price of $20.1. On debut today, the stock opened at $35.5, up 76.6% from the listing price of $20.1, 7.93 million shares traded at market open.(HK stocks quote is delayed for at least 15 mins.)

AASTOCKS News

IMPACT THERAP-B Opens Up 76.6% to $35.5 on Debut

IMPACT THERAP-B(07630.HK)

Precision-Drug maker Impact Therapeutics Ignites IPO Frenzy

Hong Kong stocks "synthetic death" first stock IMPACT THERAP-B first listing stock price doubled

IMPACT THERAP-B Opens Up 76.6% to $35.5 on Debut